Newsroom | Press Releases

Seno Medical Elects Joseph C. McNay

SAN ANTONIO, TEXAS — August 4, 2006 – Seno Medical Instruments, Inc., a San Antonio medical device company specializing in the early detection of cancer, announced today Joseph C. McNay of Boston, Massachusetts will join its Board of Directors. McNay joins Seno Medical Instruments at an exciting time for the company. Seno recently announced it has received $3 (M) million dollars in funding to launch commercial operations. This funding will allow the company to further develop patented laser optoacoustic breast imaging technology for commercial use by doctors and hospitals around the world.

McNay currently serves as President of the Boston Securities Analyst Society (BSAS), a non-profit association founded as a forum for the exchange of information in the investment community. It currently serves over 4,500 members. McNay is also the Chairman and Chief Investment Officer and Managing Principal of Essex Investment Management Company, LLC. Prior to founding Essex in 1976, he was Executive Vice President and Director of Endowment Management and Research Corp. for nine years.

McNay, esteemed in the global business community for his investment expertise, is also well-regarded as a leader in the medical community. He currently serves as a Trustee of the Dana Farber Cancer Institute and on the Investment Committee of Children’s Hospital Boston. McNay is head of the Advisory Committee for the Juda Folkman Foundation, which supports Dr. Juda Folkman for his research at Children’s Hospital Boston. In addition to serving on Seno Medical’s Board of Directors, he will continue to serve on the Board of Directors at the biotechnology company, ReGenRx Biopharmaceuticals, Inc.

McNay is admired for sharing his investment knowledge as a Trustee of National Public Radio, the Boston Ballet and the Woods Hole Oceanographic Institution. He is a Yale University graduate with an M.B.A. from the Wharton School of Finance.

“As we persist in growing Seno Medical Instruments, we continue to look for outstanding people like Joe McNay to bring levels of expertise we can depend on to reach our goals,” said Janet Campbell, Seno Medical CEO. “We anticipate Joe’s extensive experience in both investment and medical arenas to positively impact our future growth.”

More Seno Press Releases

Seno Medical® Receives Innovative Technology Contract from Vizient For its Imagio® Breast Imaging System
Contract awarded for products that bring improvement to healthcare industry [SAN ANTONIO, TX – November...
Real World Use of OA Imaging Confirms Clinical Acceptability of Second Generation Imagio® Breast Imaging System
[SAN ANTONIO, TX – October 31, 2024] A study published in Academic Radiology, Exploring the Utility of...
IHE SHARAZONE Hits Major Milestone with 15 Participants, Empowering 37 Creators and 24 Consumers
[May 17, 2024] IHE-Europe is thrilled to report a major milestone for the IHE SHARAZONE, a groundbreaking...
American Medical Association Issues New CPT Code for Use of Seno Medical’s Opto-acoustic Technology in Breast Cancer Diagnosis
CPT Code 0857T Enables a Pathway for Reimbursement When Using Seno’s Imagio® Breast Imaging System to Diagnose...
Seno Medical Earns Frost & Sullivan's 2023 United States Enabling Technology Leadership Award for Delivering a More Efficient Breast Cancer Diagnosis with Its Cutting-edge Technology
Seno Medical offers highly differentiated opto-acoustic/ultrasound (OA/US) exam to diagnose breast cancer...